|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3486459D1
(de)
|
1983-09-26 |
1997-12-11 |
Udo Dr Med Ehrenfeld |
Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
|
ATE248583T1
(de)
|
1997-09-29 |
2003-09-15 |
Nektar Therapeutics |
In dosierinhalatoren verwendbare, stabilisierte zubereitungen
|
|
EP1034826A1
(en)
|
1999-03-05 |
2000-09-13 |
Reuter Chemische Apparatebau |
Co-crystallization process
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
PT1280520E
(pt)
|
2000-05-10 |
2014-12-16 |
Novartis Ag |
Pós à base de fosfolípidos para administração de fármacos
|
|
AU2001290912A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
TWI324518B
(en)
|
2001-12-19 |
2010-05-11 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
|
KR20070012407A
(ko)
|
2004-04-15 |
2007-01-25 |
아스텔라스세이야쿠 가부시키가이샤 |
2-아미노피리미딘 유도체
|
|
CA2657227A1
(en)
|
2006-07-14 |
2008-01-17 |
Novartis Ag |
Pyrimidine derivatives as alk-5 inhibitors
|
|
EA201000615A1
(ru)
|
2007-10-17 |
2010-12-30 |
Новартис Аг |
Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
|
|
US9005670B2
(en)
|
2010-01-05 |
2015-04-14 |
The Johns Hopkins University |
Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
|
|
WO2013148114A1
(en)
|
2012-03-30 |
2013-10-03 |
University Of Florida Research Foundation, Inc. |
P300/cbp inhibitors and methods of use
|
|
TW201414737A
(zh)
|
2012-07-13 |
2014-04-16 |
必治妥美雅史谷比公司 |
作爲激酶抑制劑之咪唑并三□甲腈
|
|
BR112015022861A8
(pt)
*
|
2013-03-11 |
2019-11-26 |
Abbvie Inc |
inibidores de bromodomínio
|
|
RU2015147601A
(ru)
|
2013-05-01 |
2017-06-05 |
Ф. Хоффманн-Ля Рош Аг |
С-связанные гетероциклоалкилзамещенные пиримидины и их применения
|
|
CN105979958A
(zh)
|
2013-10-11 |
2016-09-28 |
基因泰克公司 |
Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途
|
|
PL3089971T3
(pl)
|
2014-01-01 |
2021-01-25 |
Medivation Technologies Llc |
Związki i sposoby ich zastosowania
|
|
CN107223125B
(zh)
|
2014-09-17 |
2019-09-27 |
赛科理音医疗有限公司 |
sGC刺激剂
|
|
WO2016123054A2
(en)
*
|
2015-01-26 |
2016-08-04 |
The University Of North Carolina At Chapel Hill |
Kinase drug combinations and methods of use thereof
|
|
CN106146508A
(zh)
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
GB201506658D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
|
BR112018002550A2
(en)
*
|
2015-08-10 |
2018-09-18 |
Dana-Farber Cancer Institute, Inc. |
inhibitor resistance mechanism
|
|
BR112017002594A2
(pt)
*
|
2015-12-17 |
2017-12-19 |
Gilead Sciences Inc |
compostos inibidores de cinase de ligação de tank
|
|
EP3399980B1
(en)
|
2016-01-08 |
2025-07-16 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
JP2019524740A
(ja)
|
2016-07-25 |
2019-09-05 |
エピザイム インコーポレイテッド |
Ｃｒｅｂｂｐ関連癌の治療法
|
|
GB201617630D0
(en)
|
2016-10-18 |
2016-11-30 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
WO2018195450A1
(en)
|
2017-04-21 |
2018-10-25 |
Epizyme, Inc. |
Combination therapies with ehmt2 inhibitors
|
|
IT201700047189A1
(it)
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
BR112019025346A2
(pt)
|
2017-05-30 |
2020-06-30 |
Deciphera Pharmaceuticals, Inc. |
uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
|
|
EP3661519A1
(en)
|
2017-08-03 |
2020-06-10 |
Novartis AG |
Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
|
|
SG11201913249SA
(en)
|
2017-08-03 |
2020-02-27 |
Novartis Ag |
Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
|
|
JP7399848B2
(ja)
|
2017-09-01 |
2023-12-18 |
カドモン コーポレイション，リミティド ライアビリティ カンパニー |
Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
AU2018368639B2
(en)
|
2017-11-20 |
2025-02-27 |
Tolremo Therapeutics Ag |
Diagnostic method
|
|
WO2019103238A1
(ko)
*
|
2017-11-23 |
2019-05-31 |
한국과학기술원 |
Pi3k/mtor 저해제 저항성 암 치료제
|
|
GB201806320D0
(en)
|
2018-04-18 |
2018-05-30 |
Cellcentric Ltd |
Process
|
|
IL279734B2
(en)
|
2018-06-29 |
2024-11-01 |
Forma Therapeutics Inc |
Inhibiting creb binding protein (cbp)
|
|
US12290521B2
(en)
|
2018-07-25 |
2025-05-06 |
Mayo Foundation For Medical Education And Research |
Methods and materials for identifying and treating BET inhibitor-resistant cancers
|
|
WO2020035065A1
(zh)
|
2018-08-17 |
2020-02-20 |
南京明德新药研发有限公司 |
作为ret抑制剂的吡唑衍生物
|
|
CA3112043A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020055755A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
AU2019338207B2
(en)
*
|
2018-09-10 |
2025-01-02 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US12377101B2
(en)
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
AU2019407650B2
(en)
|
2018-12-17 |
2022-10-27 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
|
BR112022006394A2
(pt)
|
2019-10-02 |
2022-07-26 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
BR112022019387A2
(pt)
|
2020-03-27 |
2022-11-16 |
Dong A St Co Ltd |
Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
|
|
WO2021260110A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
|
EP4171556A1
(en)
|
2020-06-25 |
2023-05-03 |
Tolremo Therapeutics AG |
A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
|